Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04665947 | First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer | active not recruiting | Early Phase 1 | 30 | University of California, DavisOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05141643 | Imaging Study of 18F-FAC PET Scans to Assess Standard Treatment in People With Pancreatic Cancer | active not recruiting | Early Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 3, 2026 |
| clinicaltrials |
| NCT04147494 | Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues | active not recruiting | Early Phase 1 | 29 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT05041153 | Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma | active not recruiting | Early Phase 1 | 15 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05056896 | ASPIRED-XT: ASPirin Intervention for the REDuction of Colorectal Cancer Risk -EXTension | active not recruiting | Early Phase 1 | 161 | Massachusetts General HospitalOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT05245786 | An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | active not recruiting | Early Phase 1 | 14 | City of Hope Medical CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT05365893 | PHL Treatment in Pancreatic Cancer | active not recruiting | Early Phase 1 | 20 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03680586 | Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma | active not recruiting | Early Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05108428 | Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma | active not recruiting | Early Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04862260 | Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma | active not recruiting | Early Phase 1 | 3 | CHU de Quebec-Universite LavalOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03164486 | First-in-Human Positron Emission Tomography Study Using the 18F-αvβ6-Binding-Peptide | active not recruiting | Early Phase 1 | 27 | Julie L. Sutcliffe, Ph.DOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05336266 | A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma(KetoROCX) | active not recruiting | Early Phase 1 | 28 | Andrew Hendifar, MDOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04857684 | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | active not recruiting | Early Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT06853769 | Neoadjuvant Therapy for Locally Advanced Rectal Cancer(LARC-nCR01) | active not recruiting | Early Phase 1 | 48 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2025 | clinicaltrials |
Data updated 18 days agoSource updated Sep 11, 2026source: clinicaltrials